Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

DTIL – Precision BioSciences, Inc.

Float Short %

13.45

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

0.56

EPS Last/This Y

-9.22

EPS This/Next Y

1.49

Price

4.97

Target Price

30.5

Analyst Recom

1

Performance Q

6.9

Relative Volume

0.25

Beta

1.6

Ticker: DTIL




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25DTIL5.16N/AN/A0
2025-07-28DTIL5.12N/AN/A0
2025-07-29DTIL4.9N/AN/A0
2025-07-30DTIL4.79N/AN/A0
2025-07-31DTIL4.72N/AN/A0
2025-08-01DTIL4.6N/AN/A0
2025-08-04DTIL4.83N/AN/A0
2025-08-05DTIL4.85N/AN/A0
2025-08-06DTIL4.88N/AN/A0
2025-08-07DTIL4.59N/AN/A0
2025-08-08DTIL4.39N/AN/A0
2025-08-11DTIL4.29N/AN/A0
2025-08-12DTIL4.37N/AN/A0
2025-08-13DTIL4.68N/AN/A0
2025-08-14DTIL4.77N/AN/A0
2025-08-15DTIL4.66N/AN/A0
2025-08-18DTIL4.97N/AN/A0
2025-08-19DTIL4.73N/AN/A0
2025-08-20DTIL4.68N/AN/A0
2025-08-21DTIL4.79N/AN/A0
2025-08-22DTIL4.97N/AN/A0
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25DTIL5.15-147.2- -8.74
2025-07-28DTIL5.09-147.2- -8.74
2025-07-29DTIL4.89-147.2- -8.74
2025-07-30DTIL4.80-147.2- -8.74
2025-07-31DTIL4.75-147.2- -8.74
2025-08-01DTIL4.62-147.2- -8.74
2025-08-04DTIL4.84-147.2- -8.74
2025-08-05DTIL4.86-147.2- -8.74
2025-08-06DTIL4.89-147.2- -8.74
2025-08-07DTIL4.57-147.2- -8.74
2025-08-08DTIL4.38-147.2- -8.74
2025-08-11DTIL4.320.4- -8.74
2025-08-12DTIL4.400.4- -8.74
2025-08-13DTIL4.690.4- -8.74
2025-08-14DTIL4.740.4- -8.74
2025-08-15DTIL4.710.4- -8.17
2025-08-18DTIL4.971.8- -8.17
2025-08-19DTIL4.801.8- -8.17
2025-08-20DTIL4.671.8- -8.17
2025-08-21DTIL4.731.8- -8.17
2025-08-22DTIL4.971.8- -8.17
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25DTIL0.0112.4213.37
2025-07-28DTIL0.0112.4213.37
2025-07-29DTIL0.0112.4213.37
2025-07-30DTIL0.0112.4213.37
2025-07-31DTIL0.0112.4213.37
2025-08-01DTIL0.0112.4213.37
2025-08-04DTIL0.0111.4113.37
2025-08-05DTIL0.0111.4113.37
2025-08-06DTIL0.0111.4113.37
2025-08-07DTIL0.0111.4113.37
2025-08-08DTIL0.0111.4113.37
2025-08-11DTIL0.0010.8412.58
2025-08-12DTIL0.0010.8414.74
2025-08-13DTIL0.0010.8414.74
2025-08-14DTIL0.0010.8414.74
2025-08-15DTIL0.0010.8414.74
2025-08-18DTIL0.00-9.6014.74
2025-08-19DTIL0.00-9.6015.24
2025-08-20DTIL0.00-9.6015.24
2025-08-21DTIL0.00-9.6015.24
2025-08-22DTIL0.00-9.6013.45
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-2.13

Avg. EPS Est. Current Quarter

-2.21

Avg. EPS Est. Next Quarter

-1.57

Insider Transactions

Institutional Transactions

-9.6

Beta

1.6

Average Sales Estimate Current Quarter

5

Average Sales Estimate Next Quarter

5

Fair Value

Quality Score

14

Growth Score

31

Sentiment Score

74

Actual DrawDown %

99

Max Drawdown 5-Year %

-99.2

Target Price

30.5

P/E

Forward P/E

PEG

P/S

46.4

P/B

1.69

P/Free Cash Flow

EPS

-8.81

Average EPS Est. Cur. Y​

-8.17

EPS Next Y. (Est.)

-6.68

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-6205.79

Relative Volume

0.25

Return on Equity vs Sector %

-254.5

Return on Equity vs Industry %

-241.6

EPS 1 7Days Diff

0.6

EPS 1 30Days Diff

0.57

EBIT Estimation

Precision BioSciences, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 102
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-3243 for the treatment of m.3243 associated mitochondrial myopathy. In addition, the company develops PBGENE-NVS (insertion) for sickle cell and beta thalassemia diseases; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LIVER (insertion), a liver directed target; PBGENE-CNS (excision), a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with Novartis Pharma AG to discover and develop in vivo gene editing products; TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; and iECURE, Inc. to develop ARCUS-based gene-insertion therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
stock quote shares DTIL – Precision BioSciences, Inc. Stock Price stock today
news today DTIL – Precision BioSciences, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch DTIL – Precision BioSciences, Inc. yahoo finance google finance
stock history DTIL – Precision BioSciences, Inc. invest stock market
stock prices DTIL premarket after hours
ticker DTIL fair value insiders trading